Medibank Private（MDBP.F）株式概要メディバンク・プライベート・リミテッドは、オーストラリアで民間医療保険と医療サービスを提供している。 詳細MDBP.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長2/6過去の実績3/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より32.7%で取引されている 収益は年間11.52%増加すると予測されています リスク分析株式の流動性は非常に低い 3.92%の配当は、利益やフリーキャッシュフローによって十分にカバーされていない すべてのリスクチェックを見るMDBP.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$3.6317.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture011b2016201920222025202620282031Revenue AU$11.3bEarnings AU$598.7mAdvancedSet Fair ValueView all narrativesMedibank Private Limited 競合他社PrimericaSymbol: NYSE:PRIMarket cap: US$8.6bGlobe LifeSymbol: NYSE:GLMarket cap: US$11.7bLincoln NationalSymbol: NYSE:LNCMarket cap: US$6.8bUnum GroupSymbol: NYSE:UNMMarket cap: US$12.9b価格と性能株価の高値、安値、推移の概要Medibank Private過去の株価現在の株価AU$3.6352週高値AU$3.6352週安値AU$2.78ベータ0.0541ヶ月の変化30.58%3ヶ月変化30.58%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化91.05%最新ニュースお知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.お知らせ • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.お知らせ • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.最新情報をもっと見るRecent updatesお知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.お知らせ • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.お知らせ • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.お知らせ • Mar 01Medibank Private Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2024, Payable on March 26, 2025Medibank Private Limited announced ordinary dividend of AUD 0.07800000 per security for the six months ended December 31, 2024. Record Date: March 7, 2025, Ex Date: March 6, 2025 and Payment Date: March 26, 2025.お知らせ • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025お知らせ • Sep 13Medibank Private Limited, Annual General Meeting, Nov 13, 2024Medibank Private Limited, Annual General Meeting, Nov 13, 2024. Location: the edge auditorium, federation square, corner swanston street and flinders street, melbourne Australiaお知らせ • Aug 24Medibank Private Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on September 26, 2024Medibank Private Limited announced Ordinary fully franked dividend of AUD 0.09400000 per share for the six months ended June 30, 2024. Ex Date is September 4, 2024. Record Date is September 5, 2024. Payment Date is September 26, 2024.お知らせ • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024お知らせ • Oct 05Medibank Private Limited Announces Changes to Executive Leadership TeamMedibank Private Limited announced changes to its executive leadership team. Felicia Trewin will be appointed Group Lead - Data & Technology and Robert Read will be appointed Group Lead - Amplar Health. The latter follows Dr. Andrew Wilson's decision to step back from the executive leadership team and take on the role of Group Chief Medical Officer in a part time capacity. As Group Lead - Data & Technology, Felicia will have a dedicated focus on technology, security, data management and core platforms. Felicia has been Chief Technology Officer at AMP since March 2022. She has more than 25 years of experience in technology including having been the CIO at AustralianSuper, and having previously worked at ANZ, Deloitte, Microsoft and Accenture. Felicia will begin in the role in early 2024 with Kylie Williamson continuing to act in the role until that time. As Group Lead - Amplar Health, Rob will be responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of PHI business and external customers in the private and public sector, including telehealth, in-home care, and healthcare investments. Rob joined Medibank in June 2022 as Amplar Health Chief Commercial Officer. In this role he has been responsible for evolving the health services strategy including focus on virtual health and growing prevention services. Prior to that, Rob was CEO and MD at MedAdvisor Ltd. and has also held senior roles at GSK PLC and as an investor in both venture capital and private equity. Rob will begin in the role on 13 November 2023 with a transition period with Andrew. As Group Chief Medical Officer, Andrew will be responsible for clinical oversight across the business as look to support the triple aim of health: better outcomes, better affordability and better experiences. Andrew has 25 years of experience in the health system and remains a practising clinician and lecturer. Andrew will continue to represent Medibank on a number of investment Boards. Andrew will transition to the role of Group Chief Medical Officer and will carry out the role on a part time basis. Andrew will report to CEO David Koczkar in his new role. As a result of these changes, the executive leadership team will comprise: Chief Executive Officer, David Koczkar Group Lead - People, Spaces & Sustainability, Kylie Bishop Group Lead - Digital & Ventures, Rob Deeming Group Lead - Chief Customer Officer, Milosh Milisavljevic Group Lead - Trust, Legal & Compliance, Group General Counsel and Company Secretary, Mei Ramsay Group Lead - Amplar Health, Robert Read Group Lead - Chief Financial Officer & Group Strategy, Mark Rogers Group Lead - Policy, Advocacy & Reputation, Meaghan Telford Group Lead - Data & Technology, Felicia Trewin.お知らせ • Sep 21Anna Bligh to Retire as Non-Executive Director of Medibank Private Limited At the Conclusion its Annual General Meeting on 22 November 2023Medibank Private Limited announced that non-executive director, Anna Bligh has decided to retire from the Board at the conclusion of the Medibank Annual General Meeting on 22 November 2023. Anna joined the Board in December 2012 and has been a member of the Risk Management Committee,People and Remuneration Committee and the Investment and Capital Committee. Anna joined the Board prior to Medibank's listing on the Australian Securities Exchange ushering the company through the transition from government-owned to privatisation. Anna has brought extensive experience in leadership and public policy, including in healthcare.お知らせ • Aug 24Medibank Private Limited Fully Franked Final Ordinary Dividend for the Six Months Ended 30 June 2023, Payable on 5 October 2023Medibank Private Limited announced that a fully franked final ordinary dividend of 8.30 cents per ordinary share was determined on 24 August 2023 in respect of the six months ended 30 June 2023. This dividend is payable on 5 October 2023 to shareholders on the register at close of business on 14 September 2023. Ex dividend date is September 13, 2023.お知らせ • Jul 28Medibank Private Limited Announces Executive Changes, Effective 31 July 2023Medibank Private Limited announced the executive leadership changes: Group Lead - Chief Financial Officer & Group Strategy - Mark Rogers continues to hold this role with responsibility for finance, actuarial, treasury, internal audit, investor relations, strategy development and M&A. Mark adds procurement to his portfolio of responsibilities. Group Lead - Chief Customer Officer - Milosh Milisavljevic will take on this expanded role. This role brings together the Medibank and ahm brands including marketing, customer channels, customer portfolios, Live Better and diversified insurance. Group Lead - Chief Executive Amplar Health - Dr. Andrew Wilson continues in this role. Andrew is responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of business and government, including telehealth, in-home care, and investments in primary care and ambulatory care. Group Lead - Digital & Ventures - Rob Deeming takes on a new role to accelerate growth in health through the development of digitally-led health products and services for customers and the community. Rob maintains his responsibility for the group digital team supporting insurance and health businesses. Group Lead - Data & Technology - this role will have a dedicated focus on technology, data management and core platforms. An internal and external recruitment process is underway. In the interim Kylie Williamson will continue to act in this role. Group Lead - Trust, Legal & Compliance and Company Secretary - Mei Ramsay will continue to hold this role, with responsibility for customer trust added to her existing portfolio of legal, governance, compliance and regulatory affairs. Mei continues as Company Secretary. Group Lead - People, Spaces & Sustainability - Kylie Bishop will continue to hold this role, with additional responsibility for spaces (property). Kylie continues to lead the key people functions, as well as leading environmental, social and governance focus areas. Group Lead - Policy, Advocacy & Reputation - this is a new role to the executive leadership team. Meaghan Telford will have responsibility for government and industry relations, health stakeholders, health policy, reputation and external communications. Meaghan has been with the company for more than 7 years. These roles report directly to the CEO. The changes are effective 31 July 2023.お知らせ • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023お知らせ • Feb 07Medibank Announces Class Action Filed in the Federal Court of AustraliaMedibank announced class action against Medibank was filed in the Federal Court of Australia. Medibank understands that these proceedings have been brought on behalf of current and former customers in relation to the cybercrime event Medibank has previously reported and are being brought by Baker & McKenzie and funded by Omni Bridgeway. The statement of claim includes allegations of breach of contract, contraventions of the Australian Consumer Law, and breach of equitable obligations of confidence. Medibank continues to support its customers from the impact of the cybercrime through our previously announced Cyber Response Support Program which includes mental health and wellbeing support, identity protection and financial hardship measures.お知らせ • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023株主還元MDBP.FUS InsuranceUS 市場7D30.6%-1.3%2.2%1Yn/a-9.9%31.1%株主還元を見る業界別リターン: MDBP.FがUS Insurance業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: MDBP.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is MDBP.F's price volatile compared to industry and market?MDBP.F volatilityMDBP.F Average Weekly Movementn/aInsurance Industry Average Movement4.3%Market Average Movement7.3%10% most volatile stocks in US Market16.1%10% least volatile stocks in US Market3.2%安定した株価: MDBP.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のMDBP.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19763,604David Koczkarwww.medibank.com.auメディバンク・プライベート・リミテッドはオーストラリアで民間医療保険と医療サービスを提供している。同社は医療保険とメディバンク・ヘルスという2つのセグメントで事業を展開している。健康保険事業では、加入者に病院での治療を保障する病院保険や、歯科、眼鏡、理学療法などの医療サービスを保障する付帯保険などの民間医療保険商品を提供している。このセグメントでは、海外からの旅行者や留学生向けの医療保険商品も提供している。メディバンク・ヘルス部門は、政府および法人顧客向けに、健康管理、在宅介護サービス、各種遠隔医療サービスを提供し、旅行保険、生命保険、ペット保険商品を販売している。メディバンクとアームのブランドで医療保険商品を引き受けている。同社は1976年に設立され、オーストラリアのドックランズに本社を置いている。もっと見るMedibank Private Limited 基礎のまとめMedibank Private の収益と売上を時価総額と比較するとどうか。MDBP.F 基礎統計学時価総額US$9.16b収益（TTM）US$335.75m売上高(TTM)US$6.35b27.3xPER（株価収益率1.4xP/SレシオMDBP.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MDBP.F 損益計算書（TTM）収益AU$8.77b売上原価AU$6.84b売上総利益AU$1.93bその他の費用AU$1.46b収益AU$463.40m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.17グロス・マージン21.97%純利益率5.28%有利子負債／自己資本比率1.5%MDBP.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.9%現在の配当利回り110%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 03:17終値2026/05/08 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medibank Private Limited 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Andrew AdamsBarrenjoey Markets Pty LimitedJohn HesterBell PotterFreya KongBofA Global Research17 その他のアナリストを表示
お知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.
お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026
お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.
お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.
お知らせ • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.
お知らせ • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.
お知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.
お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026
お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.
お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.
お知らせ • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.
お知らせ • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.
お知らせ • Mar 01Medibank Private Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2024, Payable on March 26, 2025Medibank Private Limited announced ordinary dividend of AUD 0.07800000 per security for the six months ended December 31, 2024. Record Date: March 7, 2025, Ex Date: March 6, 2025 and Payment Date: March 26, 2025.
お知らせ • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025
お知らせ • Sep 13Medibank Private Limited, Annual General Meeting, Nov 13, 2024Medibank Private Limited, Annual General Meeting, Nov 13, 2024. Location: the edge auditorium, federation square, corner swanston street and flinders street, melbourne Australia
お知らせ • Aug 24Medibank Private Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on September 26, 2024Medibank Private Limited announced Ordinary fully franked dividend of AUD 0.09400000 per share for the six months ended June 30, 2024. Ex Date is September 4, 2024. Record Date is September 5, 2024. Payment Date is September 26, 2024.
お知らせ • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024
お知らせ • Oct 05Medibank Private Limited Announces Changes to Executive Leadership TeamMedibank Private Limited announced changes to its executive leadership team. Felicia Trewin will be appointed Group Lead - Data & Technology and Robert Read will be appointed Group Lead - Amplar Health. The latter follows Dr. Andrew Wilson's decision to step back from the executive leadership team and take on the role of Group Chief Medical Officer in a part time capacity. As Group Lead - Data & Technology, Felicia will have a dedicated focus on technology, security, data management and core platforms. Felicia has been Chief Technology Officer at AMP since March 2022. She has more than 25 years of experience in technology including having been the CIO at AustralianSuper, and having previously worked at ANZ, Deloitte, Microsoft and Accenture. Felicia will begin in the role in early 2024 with Kylie Williamson continuing to act in the role until that time. As Group Lead - Amplar Health, Rob will be responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of PHI business and external customers in the private and public sector, including telehealth, in-home care, and healthcare investments. Rob joined Medibank in June 2022 as Amplar Health Chief Commercial Officer. In this role he has been responsible for evolving the health services strategy including focus on virtual health and growing prevention services. Prior to that, Rob was CEO and MD at MedAdvisor Ltd. and has also held senior roles at GSK PLC and as an investor in both venture capital and private equity. Rob will begin in the role on 13 November 2023 with a transition period with Andrew. As Group Chief Medical Officer, Andrew will be responsible for clinical oversight across the business as look to support the triple aim of health: better outcomes, better affordability and better experiences. Andrew has 25 years of experience in the health system and remains a practising clinician and lecturer. Andrew will continue to represent Medibank on a number of investment Boards. Andrew will transition to the role of Group Chief Medical Officer and will carry out the role on a part time basis. Andrew will report to CEO David Koczkar in his new role. As a result of these changes, the executive leadership team will comprise: Chief Executive Officer, David Koczkar Group Lead - People, Spaces & Sustainability, Kylie Bishop Group Lead - Digital & Ventures, Rob Deeming Group Lead - Chief Customer Officer, Milosh Milisavljevic Group Lead - Trust, Legal & Compliance, Group General Counsel and Company Secretary, Mei Ramsay Group Lead - Amplar Health, Robert Read Group Lead - Chief Financial Officer & Group Strategy, Mark Rogers Group Lead - Policy, Advocacy & Reputation, Meaghan Telford Group Lead - Data & Technology, Felicia Trewin.
お知らせ • Sep 21Anna Bligh to Retire as Non-Executive Director of Medibank Private Limited At the Conclusion its Annual General Meeting on 22 November 2023Medibank Private Limited announced that non-executive director, Anna Bligh has decided to retire from the Board at the conclusion of the Medibank Annual General Meeting on 22 November 2023. Anna joined the Board in December 2012 and has been a member of the Risk Management Committee,People and Remuneration Committee and the Investment and Capital Committee. Anna joined the Board prior to Medibank's listing on the Australian Securities Exchange ushering the company through the transition from government-owned to privatisation. Anna has brought extensive experience in leadership and public policy, including in healthcare.
お知らせ • Aug 24Medibank Private Limited Fully Franked Final Ordinary Dividend for the Six Months Ended 30 June 2023, Payable on 5 October 2023Medibank Private Limited announced that a fully franked final ordinary dividend of 8.30 cents per ordinary share was determined on 24 August 2023 in respect of the six months ended 30 June 2023. This dividend is payable on 5 October 2023 to shareholders on the register at close of business on 14 September 2023. Ex dividend date is September 13, 2023.
お知らせ • Jul 28Medibank Private Limited Announces Executive Changes, Effective 31 July 2023Medibank Private Limited announced the executive leadership changes: Group Lead - Chief Financial Officer & Group Strategy - Mark Rogers continues to hold this role with responsibility for finance, actuarial, treasury, internal audit, investor relations, strategy development and M&A. Mark adds procurement to his portfolio of responsibilities. Group Lead - Chief Customer Officer - Milosh Milisavljevic will take on this expanded role. This role brings together the Medibank and ahm brands including marketing, customer channels, customer portfolios, Live Better and diversified insurance. Group Lead - Chief Executive Amplar Health - Dr. Andrew Wilson continues in this role. Andrew is responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of business and government, including telehealth, in-home care, and investments in primary care and ambulatory care. Group Lead - Digital & Ventures - Rob Deeming takes on a new role to accelerate growth in health through the development of digitally-led health products and services for customers and the community. Rob maintains his responsibility for the group digital team supporting insurance and health businesses. Group Lead - Data & Technology - this role will have a dedicated focus on technology, data management and core platforms. An internal and external recruitment process is underway. In the interim Kylie Williamson will continue to act in this role. Group Lead - Trust, Legal & Compliance and Company Secretary - Mei Ramsay will continue to hold this role, with responsibility for customer trust added to her existing portfolio of legal, governance, compliance and regulatory affairs. Mei continues as Company Secretary. Group Lead - People, Spaces & Sustainability - Kylie Bishop will continue to hold this role, with additional responsibility for spaces (property). Kylie continues to lead the key people functions, as well as leading environmental, social and governance focus areas. Group Lead - Policy, Advocacy & Reputation - this is a new role to the executive leadership team. Meaghan Telford will have responsibility for government and industry relations, health stakeholders, health policy, reputation and external communications. Meaghan has been with the company for more than 7 years. These roles report directly to the CEO. The changes are effective 31 July 2023.
お知らせ • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023
お知らせ • Feb 07Medibank Announces Class Action Filed in the Federal Court of AustraliaMedibank announced class action against Medibank was filed in the Federal Court of Australia. Medibank understands that these proceedings have been brought on behalf of current and former customers in relation to the cybercrime event Medibank has previously reported and are being brought by Baker & McKenzie and funded by Omni Bridgeway. The statement of claim includes allegations of breach of contract, contraventions of the Australian Consumer Law, and breach of equitable obligations of confidence. Medibank continues to support its customers from the impact of the cybercrime through our previously announced Cyber Response Support Program which includes mental health and wellbeing support, identity protection and financial hardship measures.
お知らせ • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023
